VRCA - Verrica Pharmaceuticals Inc. (VRCA) Q1 2024 Earnings Call Transcript
2024-05-13 11:49:09 ET
Verrica Pharmaceuticals, Inc. (VRCA)
Q1 2024 Earnings Conference Call
May 13, 2024, 8:30 am ET
Company Participants
Chris Calabrese - MD, LifeSci Advisors
Ted White - President & CEO
Joe Bonaccorso - CCO
Terry Kohler - CFO
Gary Goldenberg - CMO
Chris Hayes - Chief Legal Officer
Conference Call Participants
Stacy Ku - TD Cowen
Anish Nikhanj - RBC Capital Markets
Glen Santangelo - Jefferies
Oren Livnat - H.C. Wainwright
Serge Belanger - Needham and Company
Kemp Dolliver - Brookline Capital Markets
Presentation
Operator
Ladies and gentlemen, good morning, and welcome to the Verrica Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Chris Calabrese from LifeSci Advisors. Please go ahead.
Chris Calabrese
Thank you, Operator. Hello, everyone, and welcome to Verrica Pharmaceuticals first quarter 2024 corporate update and earnings conference call.
With me on the line this morning are Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals; Joe Bonaccorso, Chief Commercial Officer; Terry Kohler, Chief Financial Officer; Dr. Gary Goldenberg, Verrica's Chief Medical Officer; and Chris Hayes, Verrica's Chief Legal Officer.
As a reminder, during today's call, management will make forward-looking statements. These statements may include expectations related to the launch and commercialization of YCANTH for the treatment of molluscum contagiosum in the United States, regulatory developments, the developments of Verrica's product candidates, our expected cash runway, our potential agreements with Torii and Dormer Labs, as well as overall business strategy and planned operations....
Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript